Physician profile
John B Nelson
NPI 1417040890
$1,165.05
in general payments reported to CMS, 2019-2025
15 companies · $552 in 2025
The $552 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2022: $54.23 · 2023: $340 · 2024: $112 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $787 · Education: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $786.67 |
| Education | $217.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $357.07 | 2022-2025 | Wakix |
| Glaxosmithkline, LLC. | $148.11 | 2023 | Arexvy, Trelegy Ellipta, Nucala |
| Abiomed | $145.96 | 2023 | Impella |
| Genzyme Corporation | $124.10 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $112.83 | 2023-2025 | |
| Insmed, INC. | $74.35 | 2024-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $49.77 | 2024 | Prolastin-C Liquid |
| Inogen, INC. | $28.36 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Resmed Corp | $23.56 | 2025 | |
| Amgen INC. | $19.81 | 2025 | Tezspire |
| Astrazeneca Pharmaceuticals Lp | $18.96 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $18.34 | 2025 | Dupixent |
| Mylan Specialty L.P. | $15.44 | 2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.90 | 2019 | |
| Viatris Specialty LLC | $13.49 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.